Fennec Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Fennec Pharmaceuticals Inc.
- Former names
- Adherex Technologies Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- British Columbia, Canada
- Headquarters city
- Research Triangle Park
- Headquarters state / province
- North Carolina
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- FENC
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001211583
Board of directors
-
Adrian Haigh · DirectorSince 2023
-
Chris A. Rallis · DirectorSince 2023
-
Jeffrey S. Hackman · Director · Chief Executive OfficerSince 2024
-
Jodi A. Cook · DirectorSince 2023
-
Khalid Islam · DirectorSince 2023
-
Marco Maria Brughera · DirectorSince 2023
-
Rosty Raykov · Director · CHIEF EXECUTIVE OFFICERSince 2023
Chief executives
Jeffrey S. Hackman
· Chief Executive Officer
Since August 2024
Rosty Raykov
· CHIEF EXECUTIVE OFFICER
Until August 2024
· Former
Director election results
Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
98.8%
-
99.1%
-
99.3%
-
99.4%
-
99.6%
Board connections
1 of this board's directors also sit on 1 other board.
- via Khalid Islam
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $12,653,680
- 24 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Marco Maria Brughera Director | Option exercise | +15,545 | $2.11 | $32,800 |
| Sep 15, 2026 | Marco Maria Brughera Director | Open-market sale | −15,545 | $10.29 | $159,958 |
| Sep 1, 2026 | Rosty Raykov Former Director | Open-market sale | −10,000 | $12.11 | $121,100 |
| Aug 31, 2026 | Andrade Robert Officer (CHIEF FINANCIAL OFFICER) | Grant or award | +1,703 | — | — |
| Aug 31, 2026 | Cioffi Christiana Marie Officer (Chief Strategy Officer) | Grant or award | +156 | — | — |
| Aug 31, 2026 | Evans Terry L Officer (Chief Commercial Officer) | Grant or award | +168 | — | — |
| Aug 31, 2026 | Jeffrey S. Hackman Director, Officer (Chief Executive Officer) | Grant or award | +1,159 | — | — |
| Aug 31, 2026 | Sayad Pierre Sargis Officer (Chief Medical Officer) | Grant or award | +168 | — | — |
| Aug 31, 2026 | Rosty Raykov Former Director | Grant or award | +2,778 | — | — |
| Aug 31, 2026 | Sayad Pierre Sargis Officer (Chief Medical Officer) | Open-market sale | −12,000 | $12.18 | $146,160 |
| Aug 28, 2026 | Andrade Robert Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +21,928 | $5.10 | $111,833 |
| Aug 27, 2026 | Andrade Robert Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −75,000 | $11.78 | $883,500 |
| Aug 3, 2026 | Rosty Raykov Former Director | Open-market sale | −10,000 | $9.58 | $95,800 |
| Jul 31, 2026 | Andrade Robert Officer (CHIEF FINANCIAL OFFICER) | Grant or award | +1,703 | — | — |
| Jul 31, 2026 | Cioffi Christiana Marie Officer (Chief Strategy Officer) | Grant or award | +156 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.